PATENT CLAIM ANALYSIS

Application Number: 16020447
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["424", "185100"]

Abstract:
This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified α-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified α-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.

Claim (Index 29):
A pharmaceutical composition comprising the targeting construct of  claim 23  and a suitable excipient.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 94.0
- Lexical Diversity: 2.5
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15278854', '15717205', '14372730', '14905348', '14905343']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8606858988093745
- 35 USC 102 Novelty (BERT): 0.7198183274446155
- Combined Prediction Score: 0.8465991416728986
- Mean Citation Score: 776.9973539999999
- Max Citation Score: 967.632
- Similarity Product: 777.3674992876053

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test